“Stem cell treatment” is not one standardized procedure. Clinics may use the term for bone marrow aspirate concentrate (BMAC), fat-derived products, culture-expanded cells, donor tissue products, umbilical-cord products, exosomes, or other preparations that differ in source, processing, cell content, regulation, and evidence.
That variation is the first thing a patient needs to understand.
What is BMAC?
Bone marrow aspirate is collected—often from the pelvis—and concentrated before injection. The final product contains platelets, white cells, signaling molecules, and a small proportion of progenitor cells. BMAC should not be assumed to be the same as a purified or culture-expanded stem-cell product.
What does FDA say?
FDA states that regenerative medicine products marketed as stem-cell, exosome, adipose-derived, umbilical-cord, Wharton’s Jelly, or amniotic-fluid products have not been approved for orthopedic conditions such as osteoarthritis or knee pain.
Some autologous tissues may be used under a different regulatory framework depending on how they are processed and used. That does not mean FDA has established that they are effective for knee arthritis.
What does the evidence show?
Studies of BMAC and other cell-based injections sometimes report improvements in pain or function. However:
- Preparations and cell counts vary.
- Many studies are small or lack strong comparison groups.
- Improvements may not be greater than PRP, placebo, or other injections.
- Structural cartilage regeneration has not been established as a predictable clinical result.
- Evidence for one preparation should not be generalized to a different commercial product.
AAOS describes the evidence for stem-cell treatments in orthopaedics as mixed and not yet strong.
Questions that expose what is actually being sold
- What is the exact product and tissue source?
- Is it taken from me or obtained from a donor?
- How is it processed, concentrated, or expanded?
- What is the FDA status for this exact product and use?
- Is the clinic claiming cartilage regrowth, and what human evidence supports that claim?
- What randomized evidence compares it with PRP, placebo, or standard care?
- What adverse events and contamination controls are documented?
- What is the total out-of-pocket cost, including repeat injections?
- Is participation part of an FDA-authorized clinical trial?
Why KneeLife is not launching a provider directory yet
A directory would imply that provider availability is the main problem. At present, the larger problem is that products and claims are too heterogeneous to compare reliably and the regulatory status is often unclear.
KneeLife will first maintain an evidence and product taxonomy. A provider directory should be considered only if public sources can support precise, comparable fields without legitimizing unsupported marketing claims.
Bottom line
BMAC and related injections are active areas of research, but “stem cells for knee arthritis” is not a single evidence-supported product category. Patients should identify the exact preparation, evidence, regulatory status, risks, and cost before deciding.